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Abstract: Aripiprazole is a relatively novel second-generation antipsychotic belonging to the 
chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological 
proﬁ  le which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas 
all previously available antipsychotics are antagonists at D2 receptors, aripiprazole is the only 
available partial agonist at these receptors. Thus, it has been suggested that aripiprazole could 
be associated with a relatively neutral impact on bodyweight, possibly reducing risks of a det-
rimental impact on the quality of life that often complicates management for a large number 
of patients diagnosed with severe and persistent mental disorders (SPMDs) treated chronically 
with antipsychotic medications. However, data from short- and long-term reviewed studies 
indicate that the prevalence rate of clinically relevant weight gain during therapy with this drug 
is similar to that occurring during treatments with other antipsychotic agents, either typical or 
atypical. Moreover, information on the impact of aripiprazole therapy on the quality of life of 
patients diagnosed with SPMDs is scarce and characterized by conﬂ  icting results. Given these 
results, further, large, well-designed studies are needed before conﬁ  rming potential advantages 
of aripiprazole over ﬁ  rst-generation antipsychotics and other SGAs.
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Introduction
Schizophrenia is a chronic and highly disabling psychiatric disorder estimated to 
affect approximately 1% of the general population worldwide;1,2 in the United States 
alone, the disorder affects more than 2.5 million people, and it costs an estimated 
US$40 billion a year (including lost productivity).3 On the other hand, bipolar disorder 
is a lifelong illness characterized by recurrent manic, depressive, or mixed symptoms 
and episodes.4 Without adequate long-term treatment, bipolar disorder is associ-
ated with high rates of morbidity:5 it affects approximately 1.2% of the population 
(2.3 million adult Americans).6
In the last few years, second-generation antipsychotics (SGAs) have progressively 
become the ﬁ  rst-line agents in the treatment of these severe and persistent mental 
disorders (SPMDs). This change in the historical pharmacological approach to such 
disorders has been mainly due to better neurological safety of this antipsychotic 
agents, less likely to induce serious adverse events (such as extrapyramidal reactions 
and tardive dyskinesia) than ﬁ  rst-generation antipsychotics (FGAs).7 The improved 
tolerability shown by SGAs has been attributed to speciﬁ  c pharmacokinetic properties: 
whereas most of these agents evidence an antagonist activity at the D2 dopaminergic 
receptor subtypes comparable to that shown by FGAs, SGAs also have both speciﬁ  c 
antagonist properties at 5-HT2AC serotoninergic receptor subtypes and partial agonist 
properties at 5-HT1A subtypes;8 the potential importance of faster dissociation from the Neuropsychiatric Disease and Treatment 2009:5 118
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dopamine D2 receptor of these agents compared to FGAs in 
reducing the detrimental impact on central nervous system 
areas involved in regulating motor functions has been also 
highlighted.9,10,11
Unfortunately, however, SGAs are not devoid of other 
severe adverse events, especially during long-term treat-
ments: indeed, this class of drugs introduced onto the market 
in the mid-1990s has been associated with a wide range of 
other adverse reactions, such as hyperprolactinemia12 (which 
may lead to adverse sexual effects, including gynecomastia 
and galactorrhea), weight gain, diabetes mellitus, metabolic 
syndrome,13 and prolongation of corrected QT (QTc) interval 
on electrocardiograms (ECGs).14 All these adverse effects 
are associated with increased rates of treatment discontinu-
ation and relevant long-term health risk.15,16 Therefore, the 
development of new SGAs characterized by a good proﬁ  le 
of metabolic and cardiac tolerability is a coherent research 
direction in the quest for an optimal pharmacological 
management of SPMDs.
Aripiprazole is a relatively novel SGA belonging to the 
chemical class of benzisoxazole derivatives, characterized 
by a unique pharmacological proﬁ  le (see Table 1) which 
suggests that the drug acts as a dopamine-serotonin system 
stabilizer.17 Most relevant, whereas all previously available 
antipsychotics are antagonists at D2 receptors,18 aripiprazole 
is the only available partial agonist at these receptors.19
It has been hypothesized that the relatively low afﬁ  nity 
at H1 histaminergic receptor subtypes shown by aripiprazole 
could theoretically be associated with a relatively neutral 
impact on bodyweight. However, this ﬁ  nding remains con-
troversial:13 for this reason, this review ﬁ  rstly aims to attempt 
to deﬁ  nitively assess this relevant clinical point.
Despite the still-open debate about the potential rela-
tionship between aripiprazole therapy and increased risks of 
weight gain and other metabolic complications,13,20,21 it has 
been also stated that this speciﬁ  c facet of the safety proﬁ  le of 
aripiprazole assumed on the basis of its peculiar pharmaco-
dynamic characteristics may result in a decreased detrimental 
impact on the quality of life that often complicates management 
for a large number of patients diagnosed with SPMDs treated 
chronically with antipsychotic medications.22 Nonetheless, a 
large, long-term study has already demonstrated that there is 
no disadvantage in terms of quality of life and/or symptoms in 
using FGAs rather than some SGAs;23 however, this study did 
not include patients treated with aripiprazole. Thus, another 
aspect of the effectiveness of aripiprazole which needs to be 
clariﬁ  ed (the second, but not secondary, scope if this review) 
is if its unique pharmacological proﬁ  le may truly result in the 
improvement of the quality of life of patients with SPMDs 
who necessitate short- or long-term therapy with this speciﬁ  c 
antipsychotic medication.
Methods
Electronic searches of Medline/PubMed, EMBASE, Cur-
rent Contents, and PsycINFO from 1980 to October 2008 
were conducted using the following key words: aripiprazole, 
schizophrenia, bipolar disorder, weight gain, quality of 
life (QOL). 146 studies were recognized. Inclusion criteria 
were represented by the articles which reported the prevalence 
of clinically relevant weight gain (deﬁ  ned as 7% increase 
from baseline) during either short- or long-term therapy with 
aripiprazole. Moreover, all trials which evaluated changes in 
quality of life in patients treated with aripiprazole were con-
sidered suitable for the scopes of this review. Hence, 131 arti-
cles were excluded whereas 15 studies meeting the ﬁ  rst and/or 
the second inclusion criterion were reviewed.
Results
Weight gain
Besides the well-known impact of overweight and obesity on 
physical health, both metabolic complications have also been 
associated with diminished self-esteem, ampliﬁ  ed rates of 
non-compliance with treatment regimens and, thus, increased 
risks of symptomatologic relapse.24,25 Notwithstanding this 
background, it was not until 2005 that the SGA-associ-
ated risk of weight gain was analysed comprehensively.26 
However, this analysis showed at least two limitations: the 
ﬁ  rst is data being collected from short-term studies, despite 
SGAs are routinely utilized as treatment for chronic mental 
disorders; the second is that such results were prevalently 
based on manufacturer’s data that had been used for prepar-
ing the US ofﬁ  cial labels of drugs.27 The ﬁ  rst systematic 
Table 1 Pharmacodynamic proﬁ  le of aripiprazole17,60,61,62,63,64,65,66
Receptor subtype Activity
D2 Partial agonist
D3 Partial agonist
D4 Partial agonist
a1-adrenergic Antagonist
H1 Antagonist
5-HT1A Partial agonist
5-HT2A Antagonist
5-HT2B Inverse agonist
5-HT2C Partial agonist
5-HT6 Antagonist
5-HT7 AntagonistNeuropsychiatric Disease and Treatment 2009:5 119
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review which provided original data on this topic became 
available only one year later:13 the main ﬁ  nding emerging 
from this appraisal was that the hypothesized differences 
among these agents in the liability of inducing weight gain 
decrease during long-term treatment. A second systematic 
review which approached the focus from an innovative 
point of view was published recently by Álvarez-Jiménez 
et al who concluded that, in patients with ﬁ  rst psychotic 
episode, the true magnitude of the effect might have been 
underestimated.28 Unfortunately, however, despite growing 
awareness that studies investigating risk of weight gain dur-
ing long-term treatment with SGAs have to be conducted in 
accordance with strict and rigorous methodological criteria, 
data on aripiprazole still suffer from quantitative and qualita-
tive limitations.
Short/medium-term studies 
on schizophrenic/schizoaffective patients
A multicenter, double-blind, placebo-controlled, parallel-
group trial investigated the effectiveness of aripiprazole 
(20–30 mg/day, ﬁ  xed doses) in in-patients with acute psy-
chotic exacerbation.29 Patients prescribed aripiprazole were 
compared with two groups of patients receiving ﬁ  xed doses 
(6 mg/day) of risperidone or placebo, respectively. In both 
active treatment groups, the rate of prevalence of clinically 
relevant weight gain (7% increase versus initial weight) 
was signiﬁ  cantly higher than that shown by the placebo 
group. Regrettably, the study provided no information about 
potential differences in the liability of inducing weight gain 
between aripiprazole and risperidone. Moreover, this study 
was conducted on institutionalized patients who, presumably, 
were on ﬁ  xed dietary regimen: for this reason, it is reason-
able to assume that the prevalence rate of clinically relevant 
weight gain recorded in these patients could not reﬂ  ect the 
rate recordable in a real world setting. In any case, in a 
subsequent study conducted on patients of speciﬁ  c ethnicity 
between these two SGAs,30 no differences were found in the 
liability for inducing weight gain. In a similarly designed 
study, the effectiveness of ﬁ  xed doses of aripiprazole (15 and 
30 mg/day) was compared with placebo and 10 mg/day of 
haloperidol.31 The study demonstrated that both active treat-
ments were associated with a statistically signiﬁ  cant increase 
in the incidence of clinically relevant weight gain compared 
with placebo. In fact, no statistically signiﬁ  cant differences 
were found in the liability of inducing weight change between 
aripiprazole and haloperidol. A similar tendency to induce 
weight change was also found between aripiprazole and a 
different FGA, perphenazine, in a study performed on a 
population of patients diagnosed with treatment-resistant 
schizophrenia.32
A multicenter, randomized, naturalistic study compared 
the effectiveness of aripiprazole with the standard of care 
(SOC) in community-treated schizophrenic patients.33 In this 
study too, aripiprazole was not devoid of an intrinsic liability 
to induce clinically relevant weight changes. Moreover, 
despite it being found that a higher proportion of patients 
on SOC (including olanzapine, quetiapine, and risperidone) 
had clinically relevant weight gain compared with patients 
treated with aripiprazole, no information was provided about 
the eventual statistical signiﬁ  cance of such a difference. 
However, a recent secondary analysis performed on the same 
population of patients suggested that both overall weight 
change from baseline and the difference in pattern of weight 
change over time were signiﬁ  cantly lower in aripiprazole-
treated patients than in patients on SOC.34 Unfortunately, the 
relevant information on the statistical signiﬁ  cance of the dif-
ference in the potential incidence of clinically relevant weight 
gain between the groups remained uninvestigated.
More detailed information is available in a multicenter, 
randomized, double-blind, active-control trial in patients with 
schizophrenia who were in acute relapse and required hos-
pitalization.35 At study end, a greater proportion of patients 
treated with olanzapine exhibited clinically signiﬁ  cant weight 
gain and this difference reached statistical signiﬁ  cance: 
however, these results must be interpreted with great cau-
tion because of the great percentage of patients who prema-
turely discontinued the trial (80%, approximately). In fact, 
no decrease in the prevalence of clinically relevant weight 
gain was found in a recent, multicenter, double-blind study 
investigating effects of aripiprazole in overweight patients 
with schizophrenia or schizo-affective disorder switched 
from olanzapine.36 Moreover, a smaller and shorter study was 
unable to conﬁ  rm potential favourable effects on bodyweight 
of switching patients to aripiprazole, thus suggesting this 
clinical and pharmacological strategy is ineffective in reduc-
ing prevalence of metabolic abnormalities in schizophrenic 
patients who had gained weight during treatments with other 
SGAs.37 In a recent study focused to evaluate feasibility of 
switching overweight schizophrenic patients to aripiprazole 
(in this study, the drug was used as either monotherapy or 
adjunctive therapy to clozapine or olanzapine),38 6% of these 
patients continued to show clinically relevant weight gain; 
nonetheless, the mean weight loss kg in those who had con-
tinued aripiprazole up to study end was 3.6 kg. Such results 
were consistent with those shown by a not recent, short-term 
trial.39 Short- and medium-term studies reporting prevalence Neuropsychiatric Disease and Treatment 2009:5 120
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rate of clinically relevant weight gain in patients treated with 
aripiprazole are summarized in Table 2.
Long-term studies on schizophrenic/
schizoaffective patients
A relatively large study suggested that the overall preva-
lence of weight gain in patients on long-term aripiprazole 
treatment was not different from that shown by patients 
chronically treated with haloperidol;40 however, patients 
with the lowest baseline BMI (23 kg/m2) experienced a 
signiﬁ  cantly greater weigh gain during aripiprazole than 
haloperidol treatment.
Moreover, the percentage of patients who developed 
weigh gain in a head-to-head comparison study between 
aripiprazole and olanzapine was surprisingly very low in 
both treatment groups.41 Studies reporting the prevalence of 
clinically relevant weight gain during long-term aripiprazole 
treatment are summarized in Table 3.
Short-, medium-, and long-term studies on patients 
with affective disorders
A small study was recently established in order to assess 
the effectiveness of this medication in patients with bipo-
lar depression were either inadequately responsive to, or 
poorly tolerant of, adequate treatment with at least one 
mood stabilizer.42 The study conﬁ  rmed that patients who 
received aripiprazole in addition to previous treatment were 
at a higher risk of developing weight gain, compared with 
patients who continued mood stabilizing monotherapy. 
However, the study did not show the proportion of aripip-
razole-treated patients who developed clinically relevant 
weight gain. In contrast, this information is available in a 
well-designed, 26-week study investigating the effective-
ness of aripiprazole in delaying the time of disease-relapse 
in bipolar 1 patients in acute main phase:43 the prevalence 
of clinically relevant weight gain was higher in patients 
who received aripiprazole compared with that shown by 
patients randomly assigned to the placebo group. Due to 
statistical reasons, it was not possible to estimate the relative 
risk for aripiprazole/placebo. However, the only long-term 
study so far conducted on patients diagnosed with bipolar 
disorder showed that aripiprazole therapy was associated 
with a statistically signiﬁ  cant increase in the risk of induc-
ing clinically relevant gain compared with placebo.44 Only 
negligible proportions of patients who gained more than 
7% of basal weight were reported in studies investigating 
the effectiveness of this drug in patients who had been 
hospitalized for more than 50% of the trial duration and, 
thus, had been on ﬁ  xed dietary regimen throughout aripip-
razole therapy.45
Table 2 Prevalence of clinically relevant weight gain in short/medium-term studies on schizophrenic/schizoaffective patients treated 
with aripiprazole
Study sample size (N) 
Study duration
Percentage of 
completers
ARI: doses and 
prevalence of ARI-
induced clinically 
relevant weight gain
Prevalence of 
comparator-induced 
clinically relevant
weight gain
Statistical signiﬁ  cance
Potkin et al 200337 (N = 202) 
4 weeks
63.4% 30 mg 9%
20 mg 13%
PLA 2%
RIS 11%
ARI 20 mg vs PLA p = 0.004
ARI 30 mg vs PLA p = 0.04
RIS 6 mg vs PLA p = 0.03
ARI 20–30 mg vs RIS p = N/A
Chan et al 200738 (N = 49) 
4 weeks
78% 15 mg 4% RIS 12% ARI 15 mg vs RIS p = NS
Kane et al 200739 (N = 204) 
4 weeks
62% ARI 15 mg 7%
ARI 30 mg 4%
HAL 10% ARI 30 mg vs PLA p = NS
ARI 15 mg vs PLA p  0.05
HAL 10 mg vs PLA p  0.01
ARI 15–30 mg vs HAL p = NS
Kane et al 200740 (N =154) 
6 weeks
71% 15–30 mg 2% PPH 2% ARI 15–30 mg vs PPH p = NS
Kerwin et al 200741 (N = 284) 
26 weeks
57.7% 15–30 mg 7% SOC 21.2% ARI 15–30 mg vs SOC p = N/A
McQuade et al 200443 (N = 156) 
26 weeks
≈ 80% 15–30 mg 14% OLA 37% ARI 15–30 mg vs OLA p  0.001
Abbreviations: ARI, aripiprazole; OLA, olanzapine; RIS, risperidone; HAL, haloperidol; PPH, perphenazine; PLA, placebo; SOC, standard of care; N/A, data not available; NS, 
not statistically signiﬁ  cant.Neuropsychiatric Disease and Treatment 2009:5 121
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A recent, multicenter, randomized, double-blind, 
placebo-controlled study investigated the effectiveness 
of adjunctive therapy with aripiprazole in patients diag-
nosed with major depressive disorder who had shown an 
inadequate response to at least 1 and up to 3 historical 
and 1 additional prospective antidepressant therapy.46 The 
most frequent antidepressant medications continued dur-
ing the double-blind phase were escitalopram, venlafaxine 
extended-release, and sertraline. Despite the mean daily 
dose of aripiprazole being relatively low (11.0 mg), the 
prevalence of clinically relevant weight gain was higher 
in patients who had received adjunctive therapy with 
this SGA than in those who had been assigned to placebo; 
this difference reached statistical signiﬁ  cance. Such ﬁ  ndings 
substantially replicated those that emerged from a previous, 
designed study.47 Short-, medium-, and long-term studies on 
patients with affective disorders treated with aripiprazole 
are shown in Table 4.
Quality of life
So far, only 4 studies investigating the impact of aripip-
razole therapy on the quality of life of patients have been 
published. Two of these investigated the same population of 
patients (people enrolled in the STAR study), and 3 showed 
an open-label design. In the only study which provided a 
double-blind, placebo-controlled design, aripiprazole was 
merely compared with an FGA.
In the open-label study by Kerwin et al patients who had 
been switched to aripiprazole (because current medication 
was not tolerated and/or clinical symptoms were not fully 
controlled) showed a greater improvement in the quality 
of life compared with patients who remained on SOC, as 
Table 3 Prevalence of clinically relevant weight gain in long-term studies on schizophrenic/schizoaffective patients treated with aripiprazole
Study sample size (N) 
Study duration
Percentage of 
completers
Prevalence of ARI-
induced clinically 
relevant weight gain
Prevalence of 
comparator-induced 
clinically relevant 
weight gain
Statistical signiﬁ  cance
Kasper et al 200347 
(N = 861) 52 weeks
43% 5% HAL 3% When stratiﬁ  ed by mean body 
mass index (BMI) at the baseline 
study visit, patients with the lowest 
baseline BMI (23 kg/m2) experi-
enced a signiﬁ  cantly greater weight 
gain during aripiprazole than 
haloperidol treatment p = N/A
Chrzanowski et al 200648 
(N = 155) Up to 72 weeks
71% 0% OLA 5% ARI 15–30 mg vs OLA p = N/A
Abbreviations: ARI, aripiprazole; OLA, olanzapine; HAL, haloperidol; N/A, data not available.
Table 4 Prevalence of clinically relevant weight gain in short/medium/long-term studies on patients with affective disorders treated 
with aripiprazole
Study sample size (N) 
Study duration
Psychiatric diagnosis/
percentage of 
completers
Prevalence of ARI-
induced clinically 
relevant weight gain
Prevalence of 
comparator-induced 
clinically relevant 
weight gain
Statistical signiﬁ  cance
Keck et al 200751 (N = 78) 
26 weeks
BID 50% 13% PLA 0% ARI 15–30 mg vs PLA p = N/A
Keck et al 200752 (N = 78) 
Up to 72 weeks
BID 18% 20% PLA 5% ARI 15–30 mg vs PLA p = 0.01
Keck et al 200353 (N = 130) 
3 weeks
ABM 42% 1.5% PLA 0% ARI 15–30 mg vs PLA p = N/S
Marcus et al 200854 (N = 191) 
6 weeks
MDD 82.4% 3.4% PLA 0% ARI 2–20 mg vs PLA p = 0.031
Berman et al 200755 (N = 182) 
6 weeks
MDD 87.9% 7.1% PLA 1.2% ARI 2–20 mg vs PLA p = 0.008
Abbreviations: ARI, aripiprazole; PLA, placebo; MDD, major depressive disorders; BID, bipolar I disorder; ABM, acute bipolar mania.Neuropsychiatric Disease and Treatment 2009:5 122
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demonstrated by the statistically significant changes in 
the Quality of Life Scale (QLS) total score.40 The QLS is 
a 21-item rating scale which is subdivided into 4 domains 
(interpersonal relations, instrumental role, intrapsychic 
foundations, and common objects/activities). Each of this 
domain is scored on a 7-item scale, with the lowest score 
indicating the most severe degree of dysfunction.48 However, 
as Table 5 shows, the overall discontinuation rate for either 
lack of efﬁ  cacy and/or adverse events was higher in patients 
who had been switched to aripiprazole treatment than that 
shown by patients who had continued the previous pharma-
cological regimen. A post-hoc analysis conducted on the 
same population of patients investigated other aspects of 
quality of life of these schizophrenic patients, including a 
generic measurement of health-related quality of life, through 
speciﬁ  c instruments such as the EuroQol-5D (EQ-5D).49 This 
is a simple, 5-item scale which assesses mobility, self-care, 
usual activity, pain/discomfort, and anxiety/depression.50 At 
study end (week 26), patients who started aripiprazole treat-
ment and those continuing SOC showed substantially similar 
values at the Q-5D (see Table 5). In contrast, as shown in 
Table 5, the addition of aripiprazole to clozapine induced a 
statistically signiﬁ  cant improvement in the global QLS score 
in a the third open-label study.51
On the other hand, the only double-blind, randomized 
study which attempted to compare changes in quality of life 
among patients on aripiprazole or perphenazine treatment 
failed to demonstrate any statistically signiﬁ  cant differences 
between the groups39 (see Table 5). In fact, in this study 
the mean changes in QLS score from baseline were similar 
in both groups. Moreover, the Authors reported that the 
proportion of patients experiencing a clinically important 
improvement (20% increase in QLS score from baseline) 
in QLS was higher in the aripiprazole group (36%) than in the 
perphenazine group (21%). In any case, this result (emerging 
from data from both completers and non-completers [Last 
Observation Carried Forward methodology]), did not indicate 
any statistical relevance.
Discussion
Weight gain
As regards the liability of aripiprazole to inducing weight 
gain, short/medium-term studies on schizophrenic or schizoaf-
fective patients (showing a range of duration between 4 and 
26 weeks) demonstrated that the prevalence rate of clinically 
relevant weight gain during therapy with this drug is similar 
to that occurring during treatments with other antipsychotic 
agents, either typical (haloperidol, perphenazine38,39) or 
atypical (risperidone37), and even higher than that occurring 
in patients included in placebo control-groups.37 The ﬁ  nding 
that the proportion of aripiprazole-treated patients who may 
develop clinically relevant weight gain is lower than that 
recorded in patients continuing standard of care (speciﬁ  cally, 
olanzapine, risperidone, and olanzapine) has no relevance 
in clinical practice, because no head-to-head comparison 
had been performed between aripiprazole and each of these 
SGAs.40 In addiction, the strength of conclusions emerg-
ing from the only available head-to-head comparison with 
olanzapine (aripiprazole was less likely to induce clinically 
relevant weight gain than olanzapine) is impaired by the high 
percentage of patients who prematurely discontinued this 
trial (80%, approximately).43 In fact, this difference seemed 
to disappear in a further, long-term study.49 Moreover, long-
term studies suggested that patients with low baseline BMI 
are at greater risk of developing an increase in bodyweight 
during chronic aripiprazole treatment than during chronic 
Table 5 Changes in quality of life in patients treated with aripiprazole
Study sample size (N) 
Study duration
Discontinuation rate 
for lack of efﬁ  cacy/
adverse events in the 
ARI-group
Discontinuation rate 
for lack or efﬁ  cacy-
adverse events in the 
comparator group
Improvement in the 
quality of life between 
the groups and statistical 
signiﬁ  cance
Standardized 
instruments 
used
Kerwin et al 200740 (N = 284) 
26 weeks
53.9% 46.1% ARI  SOC p  0.001 QLS
Taylor et al 200856 (Same 
population and duration of 
the Kerwin’s study)
Same population and 
duration of the Kerwin’s 
study
Same population and 
duration of the Kerwin’s 
study
ARI = SOC EQ-5D
Mitsonis et al 200758 (N = 27) 
16 weeks
7.4% N/A ARI plus CLO  CLO 
p  0.05
QLS
Kane et al 200739 (N = 154) 
16 weeks
32% 19% ARI = PPH QLS
Abbreviations: ARI, aripiprazole; SOC, standard of care; PPH, perphenazine; QLS, Quality of Life Scale; EQ-5D, EuroQol-5D; N/A, data not available.Neuropsychiatric Disease and Treatment 2009:5 123
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haloperidol treatment.48 The absence of neutrality on weight 
changes shown by aripiprazole seems to be especially mani-
fest when the drug is used as medium/long-term therapy in 
patients with affective disorder: in this speciﬁ  c psychiatric 
population, the proportion of patients who may incur iatro-
genic metabolic complications could indeed range between 
13% and 20%.51,52
Quality of life
Although quality of life is important for patients with schizo-
phrenia, it is difﬁ  cult to determine due to the fact that it relies 
on patient perception and self-evaluation, which is likely to 
be impaired by the underlying condition. Moreover, beyond 
the methodological limitations shown by studies speciﬁ  cally 
focused on aripiprazole, until now there continues to be a lack 
of agreement on deﬁ  nitions of the concept of quality of life52 
(see Table 6). In fact, quality of life is deﬁ  ned in multiple ways 
and means different things to different people. These various 
ways of deﬁ  ning quality of life range from vague deﬁ  nitions 
of “whatever the individual deﬁ  nes it to be,” “ability to lead a 
normal life” and “self-actualization,” to more thoughtful and 
considered deﬁ  nitions such as those that emphasize fulﬁ  llment 
of personal goals.53 In any case, data on the impact of aripip-
razole therapy on the quality of life of schizophrenic patients 
are scarce and characterized by conﬂ  icting results.39,40,56,58 In 
addiction, until now studies lasting more than 26 weeks are 
unavailable. Our results substantially replicate those emerging 
from unpublished data and reported in the systematic review 
by El-Sayeh and Morganti, who revealed no conclusive 
evidence of a clinically important improvement in quality of 
life among 154 patients given aripiprazole, as assessed by the 
QLS.54 These ﬁ  ndings are not surprising.
Conclusions
The speciﬁ  c receptorial afﬁ  nity of aripiprazole and, thus, 
its mechanisms for action, both have led to the hypothesis 
that medication could be considered as an interesting, safe, 
and effective medication in the psychopharmacological 
armamentarium against SPMDs compared with other anti-
psychotic agents. Unfortunately, however, the enthusiasm 
which accompanied the introduction of the drug onto market 
should be attenuated. In fact, a part from the relevant con-
cerns which seem to negate the theorized neutral effects on 
bodyweight and the positive impact on the quality of life, 
other possible advantages of the unique pharmacodynamic 
properties of aripiprazole remain doubtful.55
In fact, despite the peculiar activity of aripiprazole at 
D2 receptors ( associated with both reduced neurocognitive 
effects and an improved neurological tolerability).56,57,58 it 
has been conversely suggested that there are no beneﬁ  cial 
effects of aripiprazole on general cognitive and executive 
functioning.19 Moreover, data emerging from either short- or 
long-term studies also questions the neurological safety of 
aripiprazole which, at least in bipolar patients, seems not to 
be devoid of risk inducing EPS.59 In the light of these con-
siderations, we are forced to conclude that evidence-based 
information indicates that further, well-designed studies are 
needed before conﬁ  rming, if existing, potential advantages 
of aripiprazole over FGAs and other SGAs.
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